•				
FORM PTO-1449 (Modified)	ATTY. DOCKET NO.	SERIAL NO.	66	EGI
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT(S)' INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	14918-707 CPA4	08/846,933	AUG-6 AHI	CETTER 150
	APPLICANT		0:	70/
	Cleland et al.		(.,)	\sim
	FILING DATE	GROUP ART U	JŇĪT	300
	April 30, 1997	1641)

REFERE	NCE DE	SIGNATION U.S.	PATENT D	OCUMENTS			
EXAM'R INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	Subclass	Filing Date If Appropriate
VR	1	3,565,559	02.23.71	Sato et al.	424	37	
VR	2	3,737,337	06.05.73	Schnoring et al.	ロウ	100	
VR	*3	4,293,539	10.06.91	Ludwig et al.	424	19	
VR	4	4,389,330	06.21.83	Tice et al.	427	213,36	
VR	*5	4,524,067	06.18.85	Archi et al.	514	33	
VR	6	4,568,559	02.04.86	Nuwayser et al.	427	3	
VR	7	4,637,905	01.20.87	Gardner	264	4.3	
NR	*8	4,652,441	03.24.87	Okada et al.	424	19	
VR	9	4,675,189	06.23.87	Kent et al.	424	490	
NR	*10	4,719,246	01.12.88	Murdoch et al.	521	134	
VR	*11	4,728,721	03.01.88	Yamamoto et al.	528	36	
VR	*12	4,767,628	08.30.88	Hutchinson et al.	424	426	
VP_	*13	4,849,228	07.18.89	Yamamoto et al.	424	457	
VR	*14	4,897,268	01.30.90	Tice et al.	424	422	
VR	*15	4,902,515	02.20.90	Loomis et al.	424	486	
VR	*16	4,917,893	04.17.90	Okada et al.	424	423	
VR	17	4,919,929	04.24.90	Beck et al.	424	88	
VR	*18	4,954,298	09.04.90	Yamamoto et al.	264	4.6	
VR	*19	4,962,091	10.09.90	Eppstein et al.	514	2	
VR	*20	4,990,336	02.05.91	Silvestri et al.	424	426	
VR_	*21	5,008,116	04.16.91	Cahn	424	491	
VR	22	5,015,476	05.14.91	Cochrum et al.	424	423	
NR	*23	5,057,540	10.15.91	Kensil et al.	514	25	
VR	24	5,068,112	11.26.91	Samejima, et al.	424	495	
VR	*25	5,075,109	12.24.91	Tice et al.	424	88	
VŘ	26	5,100,669	03.31.92	Hyon et al.	424	426	
VR	27	5,126,147	06.30.92	Silvestri et al.	424	497	_

EXAMINER V.	DATE CONSIDERED 16/99					
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw						
line through citation if not in conformance and not considered. Include copy of this form with next communication						
to Applicant(s).						

(Information Disclosure Statement — Section 9 PTO-1449 (Modified) [6-1])

Docket No.: 14918-707 CPA4

ATTY. DOCKET NO.	SERIAL NO.		
14918-707 CPA4	08/846,933		
APPLICANT		55	ECH
Cleland et al.		750	
FILING DATE	GROUP ART U	NEE	74
April 30, 1997	1641	1	ER HO
		01	25 m
			-
			0 0 0 3 0
		<u>ö</u>	<u></u>

VR	*28	5,198,533	03.30.93	Schally et al.	530	313 0	Ni Co
VR	29	5,242,686	09.07.93	Chu et al.	424	92	<u> </u>
VR	30	5,348,867	09.20.94	Georgiou et al.	435	69.7	
VR	31	5,624,612	04.29.97	Sewall et al.	264	4,1	
VR	32	5,643,605	07/01/97	Cleland et al.	424	489	
VR	33	5,667,808	09/16/97	Johnson et al.	424	501	

FOREIGN PATENT DOCUMENTS

EXAM'R INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	Subclass	TRANS	LATN
							yes	no
Notavayab	*34	7,992,987	04.01.88	AU (abstract only)				
NR	35	266,119 A2	05.04.88	EPO				
VR	*36	279,688 A2	08.24.88	EPO				
VR	*37	333,523 A2	09.20.89	EPO				
VP	38	399,843 A2	11.28.90	EPO				
VR	*39	442,671 A2	08.21.91	EPO	_			
VR	*40	WO 90/03984	04.19.90	PCT				
VR	41	WO 90/09166	08.23.90	PCT				
VR	42	WO 91/12882	09.05.91	PCT				
VR	· *4 3	WO 91/15238	10.17.91	PCT				
*R	44	WO 93/07861	04.29.93	PCT			-y	
Mayailable	45	8,803,621	04.13.90	SE				

OTHER ART (Include Author, Title, Date, Pertinent Pages, etc.)

	*46	Arthur et al., "Challenge of chimpanzees (Pan troglodytes) immunized with human immunodeficiency
VR	40	virus envelope glycoprotein gp120" Journal of Virology 63 (12): 5046-5053 (1989)
	*47	Berman et al., "Human Immunodeficiency virus type 1 challenge of chimpanzees immunized with
.10		recombinant envelope glycoprotein gp120" Proc. Natl. Acad. Sci. USA 85(14): 5200-5204 (July
VC		1988)
	*48	Chang et al., "Biodegradable Semipermeable Microcapsules Containing Enzymes, Hormone,
NR		Vaccines, and Other Biologicals" J. Bioengineering 1:25-32 (1976)

EXAMINER V. R	DATE CONSIDERED	16	199	<u> </u>		
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw						
line through citation if not in conformance and not considered. Include copy of this form with next communication						
to Applicant(s).						

(Information Disclosure Statement — Section 9 PTO-1449 (Modified) [6-1])

PAGE 2 of 4

BA990280.013

Docket No.: 14918-70,7 CPA4

FORM PTO-1449 (Modified)	ATTY. DOCKET NO.	SERIAL NO.
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT(S)' INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	14918-707 CPA4	08/846,933 99 AUG - 6
•	APPLICANT Cleland et al.	REIVE Am
	FILING DATE April 30, 1997	GROUP ART UNIT 30
	11	900

	*49	Chen <u>Science</u> 262:980-981 (1993)
NR	50	Cohen, J., "Jitters Jeopardize AIDS Vaccine Trials" Science 262:980-981 (1993)
.0	*51	Cowsar et al., "Poly (lactide-co-glycolide) Microcapsules for Controlled Release of Steroids" Methods
UR.		in Enzymology 112 (Drug and Enzyme Targ) 101-116 (1985)
	*52	Eldridge et al., "Biodegradable and Biocompatible Poly (DL-lactide-Co-Glycolide) Microspheres as an
VR		Adjuvant for Staphylococcal Enterotoxin B Toxoid Which Enhances the Level of Toxin Neutralizing
VI		Antibodies" Infection and Immunity 59(9):2978-86 (1991)
NR	*53	Eldridge et al., "Biodegradable Poly (DL-lactide-coglycolide) Microspheres" Res. Immunol. 143(5)
7		557-63 (1992)
J.D	54	Esparza et al., "Parameters Affecting the Immunogenicity of Microencapsulated Tetanus Toxoid"
NR		Vaccine 10(10): 714-720 (1992)
NR	*55	Glaser, V., "Solving the HIV Vaccine Puzzle: Questions Still Outnumber the Answers" Genetic
41		Engineering News pps. 15-30 (November 1, 1993)
NR	56	Hora, et al., "Release of Human Serum Albumin from Poly(lactide-co-glycolide) Microspheres"
41-		Pharmaceutical Research 7(11):1190-1194 (1990)
VR	*57	Hu et al., "Effect of immunization with a vaccinia-HIV env recombinant on HIV infection of
V/		chimpanzees" Nature 328 (6132):721-723 (August 1987)
110	*58	Kensil et al., "Development of a genetically engineered vaccine against feline leukemia virus
VR.		infection" J. Amer. Veterinary Med. Assoc. 199(10):1423-1427 (1991)
VR	59	Kohn et al., "Single Step Immunization Using a Controlled Release, Biodegradable Polymer With
11		Sustained Adjuvant Activity" J. Immun. Methods 95:31-38 (1986)
NR	*60	Maulding, "Prolonged Delivery of Peptides by Microcapsules" J. of Controlled Release 6:167-176
41		(1987)
00	61	Nellore et al., "Evaluation of Biodegradable Microspheres as Vaccine Adjuvant for Hepatitis B Surface
VR		Antigen" Journal of Parenteral Science & Technology, Vol. 46, No. 5: 176-180 (September-October
		1992)
Not ,	*62	Numberg et al., "Adjuvant Formulations to Increase the Virus-neutralizing Antibody Response to HIV-
Ava: hab	-	1 rgp120 Subunit Vaccine" Vaccines (Annu. Meet.), Norrby et al., 11th edition, N.Y.:Cold Spring
	<u> </u>	Harbor Lab Vol. 94:23-27 (Mod. Approaches New 1994).

EXAMINER V R	DATE CONSIDERED	10	199			
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw						
line through citation if not in conformance and not considered. Include copy of this form with next communication						
to Applicant(s).			4 (5)			

(Information Disclosure Statement — Section 9 PTO-1449 (Modified) [6-1])

PAGE 3 of 4

	ATTY. DOCKET NO.	SERIAL NO.
	14918-707 CPA4	08/846,933
·	APPLICANT	
	Cleland et al.	
	FILING DATE	GROUP ART UNIT
	April 30, 1997	1641

VR	*63	O'Hagan et al., "Biodegradable Microparticles as Controlled Release Antigen Delivery System" Immunology 73(2):239-242 (1991)
VR_	64	Payne et al., "Water Soluble Phosphazene Polymers for Parenteral and Mucosal Vaccine Delivery" <u>Vaccine Design; The Subunit Adjuvant Approach,</u> Powell et al., New York, NY: Plenum Press Vol. 6:473-493 (1995)
VR	65	Preis, "A Single-step Immunization by Sustained Antigen Release" J. Immun. Methods 28:193-197 (1979)
VR	*66	Putney, S., "How Antibodies Block HIV Infection: Paths to an AIDS Vaccine" TIBS 17:191-196 (1992)
VR	67	Singh et al., "Controlled Delivery of Diptheria Toxoid Using Biodegradable Poly (D,L lactide) Microcapsules" Pharmaceutical Research 8(7): 958-961 (1991)
VR.	*68	Tabata et al., "Activation of Macrophage in Vitro to Acquire Antitumor Activity by a Muramyl Dipeptide Derivative Encapsulated in Microspheres Composed of Lactide Copolymer" <u>Journal of Controlled Release</u> 6:189-204 (1987)
VR	69	Watts et al., "Microencapsulation Using Emulsificiation/Solvent Evaporation: An Overview of Techniques and Applications" <u>Critical Reviews in therapeutic Drug Carrier Systems</u> , Vol. 7, Issue 3: 235-259 (1990)
VR	*70	White et al., "A purified Saponin Acts as an Adjuvant for a T-independent Antigen" Immunobiology of Proteins and Peptides VI, M.Z. Atassi, New York:Plenum Press pps. 207-210 (1991)
VR	*71	Wu et al., "Saponin Adjuvant Enhancement of Antigen-Specific Immune Responses To An Experimental HIV-1 Vaccine" J. of Immuno. 148(5):1519-1525 (1992)

EXAMINER V. C	DATE CONSIDERED 16/99			
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw				
line through citation if not in conformance and not considered. Include copy of this form with next communication				
to Applicant(s).				

(Information Disclosure Statement — Section 9 PTO-1449 (Modified) [6-1])

PAGE 4 of 4

Docket No.: 14918-707 CPA4